Monday, December 30, 2019

AstraZeneca, Merck score win with Lynparza approval for pancreatic cancer

AstraZeneca, Merck score win with Lynparza approval for pancreatic cancer The drug is now the only approved medicine in biomarker-selected patients with advanced pancreatic cancer.

from Moneycontrol Business News https://ift.tt/35awRrv

No comments:

Post a Comment

India a key beneficiary of global portfolio diversification: Jonathan Schiessl

Global equities are performing well despite concerns about tariffs and geopolitical issues. Investors are seemingly ignoring negative news, ...